Company / R&D Expense
Jade Biosciences, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$53.2M
FY2024
5-year range
$7.9M / $64.2M
FY2020-FY2024
Trend
-17.2%
vs FY2023
Sector context
#177 of 208
Health Care
What the data says
Jade Biosciences, Inc.'s r&d expense of $53M is lower than 85% of companies in the Health Care sector (FY2024). Improved from $39M to $53M over the past 2 years.
Based on SEC 10-K filings.
$53M in FY2024 with a 3-year CAGR of +52.5%.
Improved from $39M to $53M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +52.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 208This company $53.2M Sector average $644.3M
▼
-91.7% below sector average
Key checks
Key Insights
- 3-year CAGR of +52.5%, indicating consistent growth.
- In FY2024, r&d expense decreased 17.2% year-over-year.
- Ranks #177 out of 208 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $53.2M | -17.2% |
| FY2023 | $64.2M | +66.3% |
| FY2022 | $38.6M | +157.7% |
| FY2021 | $15.0M | +88.8% |
| FY2020 | $7.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026